
The results of therapy with zzso plus zzso zzso were compared to those obtained with zzso plus zzso zzso in a prospective zzso study of zzso zzso therapy in zzso zzso Patients were zzso into two groups: zzso group 1 zzso lymphoma, multiple zzso or zzso group 2 zzso zzso bone zzso zzso based on anticipated duration of zzso zzso zzso zzso trials were more often successful zzso zzso zzso in group 1 (55 of 62 patients or 89 per zzso than in group 2 zzso of 64 patients, 66 per zzso group 1, there was a favorable outcome in 30 of 32 zzso per zzso zzso trials and in 25 of 30 zzso per zzso zzso trials zzso zzso zzso within group 2, there was a favorable outcome in 23 of 30 zzso per zzso zzso trials and in 19 of 34 zzso per zzso zzso trials zzso zzso zzso Combined results in both groups indicated a higher proportion of favorable outcome in zzso trials zzso of 62, 85 per zzso than in zzso trials (44 of 64, 69 per zzso Further analysis zzso zzso showed the zzso difference in outcome to be significant zzso zzso zzso but the general zzso of this result may be limited by the rather low zzso of zzso bacterial infections in this zzso There was no difference between the treatment regimens in zzso zzso and serious zzso occurred only in group 2 patients (21 per cent of zzso equally divided between treatment zzso zzso protocol dosing achieved target plasma levels of zzso (3 to 8 zzso or zzso (4 to 10 zzso in 57 of 68 zzso per zzso zzso trials compared to 21 of 60 (35 per zzso zzso zzso 

